Protara Therapeutics
TARA
49 hedge funds and large institutions have $134M invested in Protara Therapeutics in 2021 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 19 increasing their positions, 9 reducing their positions, and 5 closing their positions.
111% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 9
0% more funds holding
Funds holding: 49 → 49 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
2.35% less ownership
Funds ownership: 78.29% → 75.94% (-2.3%)
37% less capital invested
Capital invested by funds: $212M → $134M (-$78.5M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.46M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$4.48M |
| 3 |
MS
Maven Securities
St Helier,
Jersey
|
+$1.43M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$1.13M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$1.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$18.9M |
| 2 |
PA
Perceptive Advisors
New York
|
-$3.47M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.12M |
| 4 |
TLP
Tri Locum Partners
New York
|
-$950K |
| 5 |
EP
Eversept Partners
New York
|
-$879K |
TARA Hedge Fund Activity: Q1 2021 in Review
49 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q1 2021, worth a combined $134M — down 37% from $212M a quarter earlier.
Fund positioning in TARA was balanced in Q1 2021: 5 funds opened new positions, 5 closed out, 19 added to existing stakes and 9 trimmed.
The largest buyer was Vanguard Group, adding an estimated $5.46M. The largest seller was Deerfield Management, exiting entirely with an estimated $18.9M sold.
- 49 institutional investors held Protara Therapeutics (TARA) as of Q1 2021, unchanged from Q4 2020.
- Funds reported $134M of Protara Therapeutics stock for Q1 2021, down 37% quarter-over-quarter.
- 5 funds opened new Protara Therapeutics positions in Q1 2021 and 5 closed out, a net change of 0 holders.
- The largest Protara Therapeutics buyer in Q1 2021 was Vanguard Group, an estimated $5.46M added.
- The largest Protara Therapeutics seller in Q1 2021 was Deerfield Management, an estimated $18.9M sold.
Based on aggregated 13F filings for Q1 2021.